REG - GlaxoSmithKline PLC - GSK Annual Report 2021 on Form 20-F

GSKAnnouncement

08/03/2022 18:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220308:nRSH1012Ea&default-theme=true

RNS Number : 1012E  GlaxoSmithKline PLC  08 March 2022

Issued: 8 March 2022, London UK

 

GlaxoSmithKline plc

Annual Report 2021 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, GlaxoSmithKline plc ("GSK") announces that on 8 March 2022 it
filed with the Securities and Exchange Commission an Annual Report on Form
20-F that included audited financial statements for the year ended 31 December
2021. GSK's 2021 Annual Report on Form 20-F is available online at GSK's
website at www.gsk.com/corporatereporting
(http://www.gsk.com/corporatereporting) and also online at www.sec.gov
(http://www.sec.gov) .

A hard copy version of the GSK 2021 Annual Report, together with the Notice of
Annual General Meeting will be available on or about 28 March 2022.

Shareholders have the ability to receive, upon request, a hard copy version of
GSK's complete audited financial statements for the year ended 31 December
2021, free of charge, by either:

(i)      writing to Equiniti Limited, our registrars in the UK, at the
following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West
Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44
(0)121 415 7067 (outside the UK);

(ii)      writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in
the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St.
Paul, MN 55164-0504, or by telephone on +1 800 990 1135 (US toll free) or +1
651 453 2128 (outside the US); or

(iii)     contacting the GSK Response Center in the USA at +1 888 825 5249
(US toll free).

 

 

 

Victoria Whyte

Company Secretary

8 March 2022

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2021.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFFTVFITIIF